%0 Journal Article
%T PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%A Addeo, Alfredo
%A Banna, Giuseppe Luigi
%J Translational Lung Cancer Research
%D 2018
%B 2018
%9 
%! PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%K 
%X We have read with great interest our Colleagues’ point of view suggesting that immunotherapy should not be integrated into the treatment of oncogene-driven non-small cell lung cancers (NSCLCs) based on currently available evidence. However, we would like to mention three points to challenge their recommendation.
%U https://tlcr.amegroups.org/article/view/23044
%P S287-S289
%@ 2226-4477